Diquafosol
| | |
| Names | |
|---|---|
| IUPAC name
[[[[(2R,3S,4R,5R)-5-(2,4-Dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate | |
| Other names
P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium | |
| Identifiers | |
| 59985-21-6 211427-08-6 (tetrasodium salt) | |
| ChEMBL | ChEMBL1767408 ChEMBL221326 |
| ChemSpider | 130647 130646 (tetrasodium salt) |
| 1736 | |
| Jmol 3D model | Interactive image |
| PubChem | 148197 148196 (tetrasodium salt) |
| UNII | 7828VC80FJ |
| |
| |
| Properties | |
| C18H26N4O23P4 | |
| Molar mass | 790.31 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010[1]. It is formulated as a 3% ophthalmic solution of the tetrasodium salt.
Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]
References
- ↑ "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.
- ↑ Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.
| ||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, April 14, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.